[go: up one dir, main page]

EE05271B1 - 7-asaindoolid, meetod nende snteesimiseks, nende kasutamine TNFa v?i fosfodiesteraas-4 inhibeerivate ravimite valmistamiseks ning neid sisaldavad ravimid - Google Patents

7-asaindoolid, meetod nende snteesimiseks, nende kasutamine TNFa v?i fosfodiesteraas-4 inhibeerivate ravimite valmistamiseks ning neid sisaldavad ravimid

Info

Publication number
EE05271B1
EE05271B1 EEP200300166A EEP200300166A EE05271B1 EE 05271 B1 EE05271 B1 EE 05271B1 EE P200300166 A EEP200300166 A EE P200300166A EE P200300166 A EEP200300166 A EE P200300166A EE 05271 B1 EE05271 B1 EE 05271B1
Authority
EE
Estonia
Prior art keywords
drugs
azaindoles
phosphodiesterase
synthesis
preparation
Prior art date
Application number
EEP200300166A
Other languages
English (en)
Inventor
H�Fgen Norbert
Egerland Ute
Kronbach Thomas
Marx Degenhard
Szelenyi Stefan
Kuss Hildegard
Polymeropoulos Emmanuel
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10053275A external-priority patent/DE10053275A1/de
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of EE200300166A publication Critical patent/EE200300166A/et
Publication of EE05271B1 publication Critical patent/EE05271B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
EEP200300166A 2000-10-27 2001-10-25 7-asaindoolid, meetod nende snteesimiseks, nende kasutamine TNFa v?i fosfodiesteraas-4 inhibeerivate ravimite valmistamiseks ning neid sisaldavad ravimid EE05271B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10053275A DE10053275A1 (de) 2000-10-27 2000-10-27 Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US24434200P 2000-10-30 2000-10-30
PCT/EP2001/012376 WO2002034747A1 (de) 2000-10-27 2001-10-25 Neue 7-azaindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung

Publications (2)

Publication Number Publication Date
EE200300166A EE200300166A (et) 2003-08-15
EE05271B1 true EE05271B1 (et) 2010-02-15

Family

ID=26007507

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300166A EE05271B1 (et) 2000-10-27 2001-10-25 7-asaindoolid, meetod nende snteesimiseks, nende kasutamine TNFa v?i fosfodiesteraas-4 inhibeerivate ravimite valmistamiseks ning neid sisaldavad ravimid

Country Status (27)

Country Link
US (3) US7169787B2 (et)
EP (1) EP1330455B1 (et)
JP (1) JP4233322B2 (et)
KR (2) KR100837099B1 (et)
CN (1) CN1247576C (et)
AR (1) AR034269A1 (et)
AT (1) ATE301121T1 (et)
AU (2) AU2175302A (et)
BG (1) BG66169B1 (et)
BR (1) BR0114903A (et)
CA (1) CA2428468C (et)
CZ (1) CZ20031146A3 (et)
DE (1) DE50106993D1 (et)
DK (1) DK1330455T3 (et)
EE (1) EE05271B1 (et)
ES (1) ES2246349T3 (et)
HR (1) HRP20030427B1 (et)
HU (1) HUP0303034A3 (et)
IL (2) IL155386A0 (et)
MX (1) MXPA03003624A (et)
NO (1) NO324947B1 (et)
NZ (1) NZ525369A (et)
PL (1) PL213999B1 (et)
PT (1) PT1330455E (et)
SK (1) SK287774B6 (et)
TW (1) TWI262920B (et)
WO (1) WO2002034747A1 (et)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
JP2006508131A (ja) * 2002-11-06 2006-03-09 セルジーン・コーポレーション 癌および他の疾患を治療および管理するための選択的サイトカイン阻害薬を用いる方法および組成物
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
CA2565965A1 (en) * 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1786813A2 (en) * 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
MX2008014450A (es) 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
WO2008026687A1 (en) 2006-09-01 2008-03-06 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor comprising the derivative
US8012992B2 (en) * 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
KR20110079669A (ko) * 2008-09-22 2011-07-07 아이시스 이노베이션 리미티드 5-아자인돌 비스포스포네이트
WO2011023696A1 (en) * 2009-08-26 2011-03-03 Nycomed Gmbh Methylpyrrolopyridinecarboxamides
WO2012072727A1 (en) 2010-12-03 2012-06-07 Biotie Therapies Gmbh Crystalline modification of n-(3,5-dichloropyridin-4-yl)-[1-(4 -fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide as inhibitor of pde4
WO2012080329A1 (en) 2010-12-17 2012-06-21 Biotie Therapies Gmbh Formulations of n-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide
CN102584842A (zh) * 2011-01-17 2012-07-18 北京大学 取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
CA3195815A1 (en) 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
CN113164487B (zh) * 2018-10-12 2024-11-26 内布拉斯加大学董事委员会 磷酸二酯酶抑制剂
WO2020180876A1 (en) 2019-03-04 2020-09-10 Beth Israel Deaconess Medical Center, Inc. Orai channel inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
WO1991009598A1 (en) 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5811432A (en) * 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
PT652868E (pt) 1992-07-28 2005-01-31 Aventis Pharma Ltd Inibidores da fosfodiesterase do amp ciclico
EP0654024A1 (en) * 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
JP3119758B2 (ja) * 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
CA2188269A1 (en) 1994-04-21 1995-11-02 Helmut Wachtel Pde iv inhibitors for treating multiple sclerosis
GB9420521D0 (en) * 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
JPH09169665A (ja) 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
AUPO282996A0 (en) * 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
JP2002539124A (ja) * 1999-03-10 2002-11-19 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物

Also Published As

Publication number Publication date
ES2246349T3 (es) 2006-02-16
AR034269A1 (es) 2004-02-18
US7419987B2 (en) 2008-09-02
HRP20030427B1 (en) 2006-04-30
DE50106993D1 (de) 2005-09-08
HK1053839A1 (en) 2003-11-07
PL213999B1 (pl) 2013-06-28
SK287774B6 (sk) 2011-09-05
US7683074B2 (en) 2010-03-23
HUP0303034A3 (en) 2012-12-28
IL155386A0 (en) 2003-11-23
BR0114903A (pt) 2003-10-14
HUP0303034A2 (hu) 2003-12-29
BG107725A (bg) 2004-08-31
PT1330455E (pt) 2005-10-31
AU2175302A (en) 2002-05-06
ATE301121T1 (de) 2005-08-15
CN1247576C (zh) 2006-03-29
CZ20031146A3 (cs) 2003-10-15
BG66169B1 (bg) 2011-10-31
KR20030065499A (ko) 2003-08-06
US20040106641A1 (en) 2004-06-03
DK1330455T3 (da) 2005-12-05
US7169787B2 (en) 2007-01-30
NO20031722D0 (no) 2003-04-14
US20060258700A1 (en) 2006-11-16
CA2428468A1 (en) 2002-05-02
CN1484644A (zh) 2004-03-24
EE200300166A (et) 2003-08-15
JP4233322B2 (ja) 2009-03-04
EP1330455B1 (de) 2005-08-03
US20080207680A1 (en) 2008-08-28
EP1330455A1 (de) 2003-07-30
AU2002221753B2 (en) 2006-12-14
CA2428468C (en) 2011-06-14
IL155386A (en) 2008-06-05
PL362837A1 (en) 2004-11-02
KR100880586B1 (ko) 2009-01-30
TWI262920B (en) 2006-10-01
NO324947B1 (no) 2008-01-07
NZ525369A (en) 2004-09-24
KR20080016758A (ko) 2008-02-21
NO20031722L (no) 2003-04-14
WO2002034747A1 (de) 2002-05-02
MXPA03003624A (es) 2004-12-02
SK5092003A3 (en) 2004-08-03
KR100837099B1 (ko) 2008-06-13
HRP20030427A2 (en) 2003-08-31
JP2004512337A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
EE05271B1 (et) 7-asaindoolid, meetod nende snteesimiseks, nende kasutamine TNFa v?i fosfodiesteraas-4 inhibeerivate ravimite valmistamiseks ning neid sisaldavad ravimid
HUP0400784A3 (en) Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them
EE05149B1 (et) Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
HUP0204410A3 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
EE05269B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
IL152889A0 (en) Imidazopyridine and imidazopyrimidine derivatives and pharmaceutical compositions containing the same
IL150734A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
HUP0300894A3 (en) Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
EE05424B1 (et) Asendatud asaindooloksoatseetpiperasiini derivaadid, neid sisaldav ravimpreparaat ning nende kasutamine ravis
HUP0401718A3 (en) Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0105133A3 (en) Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
HUP0300602A3 (en) Diazabicyclic central nervous system active agents, pharmaceutical compositions containing them and their use
EE04748B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
HUP0301722A3 (en) Pyrimidine derivatives, pharmaceutical compositions containing them and their use
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
EE200400059A (et) Diarüültsükloalküülderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
EE05109B1 (et) Sulfoonamiidi derivaadid, nende kasutamine meditsiinis ning meetod nende valmistamiseks
HUP0303524A3 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same and their use
HUP0302997A3 (en) Phenylalanine derivatives with alpha4-integrin effect, pharmaceutical compositions containing them and their use
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
IL192937A0 (en) Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and methods of using same

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20131025